Ken Griffin Adaptive Biotechnologies Corp Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 2,600 shares of ADPT stock, worth $8,814. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,600

Previous 39,300 93.38%

Holding current value

$8,814

Previous $192,000 95.83%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.88 - $4.8 $227,597 - $379,329	79,027 Added 2752.59%	81,898 $262,000
Q4 2023 Feb 14, 2024	SELL	$3.46 - $5.33 $488,278 - $752,174	-141,121 Reduced 98.01%	2,871 $14,000
Q3 2023 Nov 14, 2023	SELL	$5.07 - $8.44 $2.89 Million - $4.82 Million	-570,530 Reduced 79.85%	143,992 $784,000
Q2 2023 Aug 14, 2023	SELL	$6.19 - $8.78 $544,602 - $772,473	-87,981 Reduced 10.96%	714,522 $4.79 Million
Q1 2023 May 15, 2023	BUY	$7.8 - $10.11 $2.02 Million - $2.62 Million	259,225 Added 47.71%	802,503 $7.09 Million

Q4 2022 Feb 14, 2023	SELL	$6.26 - $9.34 $1.83 Million - $2.73 Million	-292,537 Reduced 35.0%	543,278 $4.15 Million
Q3 2022 Nov 14, 2022	BUY	$6.5 - $12.67 $2.82 Million - $5.5 Million	434,246 Added 108.14%	835,815 $5.95 Million
Q2 2022 Aug 15, 2022	BUY	$6.4 - $14.73 $1.28 Million - $2.94 Million	199,698 Added 98.92%	401,569 $3.25 Million
Q1 2022 May 16, 2022	BUY	$10.12 - $28.9 $322,332 - $920,493	31,851 Added 18.73%	201,871 $2.8 Million
Q4 2021 Feb 14, 2022	BUY	$25.17 - $36.85 $1.1 Million - $1.61 Million	43,704 Added 34.6%	170,020 $4.77 Million
Q3 2021 Nov 15, 2021	BUY	$30.02 - $39.87 $2.4 Million - $3.18 Million	79,813 Added 171.63%	126,316 $4.29 Million
Q2 2021 Aug 16, 2021	SELL	$32.22 - $44.59 $10 Million - $13.9 Million	-311,290 Reduced 87.0%	46,503 $1.9 Million
Q1 2021 May 17, 2021	BUY	$37.26 - $67.74 $13.1 Million - $23.9 Million	352,101 Added 6185.89%	357,793 $14.4 Million
Q4 2020 Feb 16, 2021	SELL	$45.01 - $65.47 $367,326 - $534,300	-8,161 Reduced 58.91%	5,692 $337,000
Q3 2020 Nov 16, 2020	SELL	$35.79 - $48.81 $1.32 Million - $1.8 Million	-36,887 Reduced 72.7%	13,853 $674,000
Q2 2020 Aug 14, 2020	BUY	$24.95 - $48.38 $368,336 - $714,233	14,763 Added 41.03%	50,740 $2.46 Million
Q1 2020 May 15, 2020	SELL	$16.96 - $34.16 $370,185 - $745,610	-21,827 Reduced 37.76%	35,977 $999,000
Q4 2019 Feb 14, 2020	SELL	$24.56 - $32.8 $1.48 Million - $1.98 Million	-60,279 Reduced 51.05%	57,804 $1.73 Million
Q3 2019 Nov 14, 2019	SELL	$30.31 - $53.51 $3.52 Million - $6.22 Million	-116,288 Reduced 49.62%	118,083 $3.65 Million
Q2 2019 Aug 14, 2019	BUY	$40.3 - $48.3 $9.45 Million - $11.3 Million	234,371 New	234,371 $11.3 Million

Others Institutions Holding ADPT

# of Institutions

200

Shares Held

146M

Call Options Held

2.6K

Put Options Held

143K

View Full List

About Adaptive Biotechnologies Corp

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $484M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

More about ADPT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account